Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02013154 · ClinicalTrials.gov registry record · Phase 1
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
A Phase 1 study of Gastric Adenocarcinoma and Squamous Cell Carcinoma, sponsored by Leap Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 151
- Enrollment target
- 10
- Study locations
NCT02013154: Completed Phase 1 study of Gastric Adenocarcinoma and Squamous Cell Carcinoma, sponsored by Leap Therapeutics.
NCT02013154 is a Phase 1 study of Gastric Adenocarcinoma and Squamous Cell Carcinoma that has completed, run by Leap Therapeutics. The registered enrollment target is 151 participants, below the 242-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (38% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02013154, a Phase 1 study of Gastric Adenocarcinoma and Squamous Cell Carcinoma, has completed, sponsored by Leap Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 151 participants
- Enrollment target
- 10
- Study locations
Study Summary
A study to evaluate the safety and tolerability of DKN-01 in combination with weekly paclitaxel or pembrolizumab in participants with relapsed or refractory Esophagogastric Malignancies
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Paclitaxel
- DRUG DKN-01 150 mg
- DRUG DKN-01 300 mg
Study Locations (10)
Massachusetts
- Dana Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
Tennessee
- Tennessee Oncology / Sarah Cannon Research Institute - Nashville
- Vanderbilt University / VICC - Nashville
Texas
- Mary Crowley Cancer Center - Dallas
- CTRC @ The University of Texas Health Science Center at San Antonio - San Antonio
California
- Cedars Sinai Medical Care Foundation - Los Angeles
Connecticut
- Smilow Cancer Hospital at Yale - New Haven - New Haven
Illinois
- Northwestern University - Chicago
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2014-05-05 |
| Est. Completion | 2021-01-11 |
| Phase | Phase 1 |
What the finished NCT02013154 record still lists
NCT02013154 is an interventional study that assigns participants to a tested intervention. The registered 151 participants enrollment target is mid-sized for trials with a published cap, below the 242-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (38% lower).
The record links to 5 conditions, with Gastric Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT02013154 lists 10 locations in 7 states (Massachusetts, Tennessee, Texas).
Frequently Asked Questions
What is clinical trial NCT02013154 about?
NCT02013154 is a clinical study titled "A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab". A study to evaluate the safety and tolerability of DKN-01 in combination with weekly paclitaxel or pembrolizumab in participants with relapsed or refractory Esophagogastric Malignancies
What is the current status of trial NCT02013154?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 151 participants. The study started on 2014-05-05. Estimated completion is 2021-01-11.
What conditions does trial NCT02013154 study?
This clinical trial studies the following conditions: Gastric Adenocarcinoma, Squamous Cell Carcinoma, GastroEsophageal Cancer, Esophageal Neoplasms, Adenocarcinoma of the Gastroesophageal Junction.
What interventions are being tested in trial NCT02013154?
The interventions under investigation include: Pembrolizumab (DRUG), Paclitaxel (DRUG), DKN-01 150 mg (DRUG), DKN-01 300 mg (DRUG).
Who is sponsoring clinical trial NCT02013154?
This trial is sponsored by Leap Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02013154 being conducted?
This trial has 10 study locations across California, Connecticut, Illinois, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02013154's enrollment target sits among peer trials
151 12th of 47 higher than 36 of 47 other Gastric Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
RECRUITING · Phase 1
-
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
RECRUITING · Phase 1
-
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RECRUITING · Phase 1
-
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01409161 · 151 participants · Phase 2
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- NCT04245397 · 151 participants · Phase 1
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
- NCT05761223 · 151 participants · Phase 1
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
- NCT07195656 · 151 participants · NA
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI